Le Lézard
Classified in: Health
Subjects: TRI, FDA

SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUStm technology


TEL AVIV, Israel, June 20, 2022 /CNW/ -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUStm) to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUStm, its innovative Ultra-Sound Ablation System.

Resistant hypertension is defined as blood pressure higher than 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses, one of which must be a diuretic. Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.

"We are very pleased that FDA has approved the REDUCED1 (Renal Denervation using Ultrasonic Catheter EmitteD energy) study. Sites initiation has started, and many clinical teams have responded very favourably about participating to the study. There is a significant number of patients that may benefit from our technology and we are genuinely happy for this important step towards the introduction of TIVUStm in the US. There is a lack of effective therapeutic solutions for patients suffering from resistant hypertension, and physicians are looking forward to a safe, effective and easy to use device treatment," says Christian Spaulding, CMO, SoniVie Ltd.

"This is a significant US Regulatory milestone for SoniVie, starting the feasibility study using the Ultra-Sound ablation platform in the US for the Renal Denervation indication. This is a major step and priority in the company's history," says Tomaso Zambelli, CEO, SoniVie LTD. 

The REDUCED1 study will further expand the Company's clinical experience based on two clinical trials in Renal Denervation performed using the earlier generation of the TIVUStm.

Renal Denervation with TIVUStm is a minimally invasive procedure that uses high-frequency non-focused Ultra-Sound energy to ablate nerves in the renal artery. This causes a reduction in the nerve activity, which may decrease blood pressure. This procedure is designed for patients who suffer from resistant hypertension.

About SoniVie

SoniVie is a medical device company developing the TIVUStm, the only Ultra-Sound Denervation platform with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease with chronic bronchitis. These diseases affect millions of patients in the United States and Europe.

Contact:
Tomaso Zambelli
+39 348 4011983
[email protected]
[email protected]

SOURCE SONIVIE


These press releases may also interest you

at 08:10
RenovoRx, Inc. , a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results...

at 08:10
HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO's HFB200301,...

at 08:07
Lillian Finance LLC, a Medical Blockchain crypto company had an incredible breakout month despite the Crypto Bear market, seeing nearly a two hundred sixty percent gain.  ...

at 08:05
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage's Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual...

at 08:05
Monod Bio, a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round. The round was led by Matrix Capital, with participation...

at 08:05
Verogen, Inc. and Gene by Gene today announced a partnership to accelerate the adoption of forensic investigative genetic genealogy. As part of the agreement, Gene by Gene, parent company of FamilyTreeDNA, will support DNA uploads generated from the...



News published on 19 june 2022 at 22:00 and distributed by: